CAY10616 is primarily utilized in research settings as a potent and selective inhibitor of Sphingosine Kinase 1 (SK1). This enzyme plays a significant role in the production of sphingosine-1-phosphate (S1P), a bioactive lipid involved in cellular signaling pathways related to inflammation, cell survival, and cancer progression. By inhibiting SK1, CAY10616 reduces S1P levels, thereby potentially suppressing inflammatory responses and inhibiting the growth and survival of cancer cells. This makes it a valuable tool in studies aimed at understanding and developing treatments for inflammatory diseases, cancer, and immune system disorders. Researchers also evaluate its efficacy and safety in preclinical models for chronic inflammation and related pathologies.